Table 1.
IC50 values for acetone extract and isolated compounds 19–22 on selected human cell lines.
| HeLa a | A549 b | MCF-7 c | DU-145 d | HEK-293 e | |
|---|---|---|---|---|---|
| Crude extract | 25.33 ± 1.23 | 9.11 ± 2.76 | 14.67 ± 2.85 | 20.88 ± 3.74 | 78.33 ± 2.11 |
| 19 | 22.67 ± 0.97 | 20.20 ± 1.99 | 20.01 ± 0.74 | 26.97 ± 2.92 | 55.87 ± 1.55 |
| 20 | 23.63 ± 0.74 | 19.13 ± 3.86 | 22.30 ± 4.05 | 26.10 ± 1.09 | 112.77 ± 3.82 |
| 21 | 3.02 ± 0.11 | 1.78 ± 0.62 | 3.16 ± 0.88 | 9.03 ± 2.11 | 124.90 ± 2.65 |
| 22 | 18.88 ± 2.06 | 13.80 ± 1.11 | 19.18 ± 2.05 | 24.21 ± 0.99 | 125.20 ± 1.98 |
| Doxorubicin | 1.55 ± 1.32 | 1.95 ± 0.97 | 1.62 ± 0.36 | 1.51 ± 0.84 | NT |
50% cell proliferation inhibitory concentration (IC50) after 48 h of compound treatment. IC50 values presented for extract is in µg/mL and for compounds in µM. a Human cervical cancer, b Human lung cancer, c Human breast cancer, d Human prostate cancer and e Normal cell lines. NT: Not tested [31].